Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

IL1R2+ Treg depletion using IL1R2-targeting ADCC-prone constructs is a potential cancer therapy to selectively target tumor-infiltrating Tregs and circumvent autoimmune complications caused by systemic Treg depletion.